Trial Profile
An Open-label Study to Assess the Efficacy and Safety of Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Expressed by an Adeno-Associated Viral Vector After Intramuscular Administration in LPL-deficient Adult Subjects.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Alipogene tiparvovec (Primary) ; Ciclosporin; Methylprednisolone; Mycophenolate mofetil
- Indications Hyperlipoproteinaemia type I; Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- Sponsors Amsterdam Molecular Therapeutics
- 28 Sep 2011 Actual initiation date (February 2009) added as reported by ClinicalTrials.gov.
- 28 Sep 2011 Actual end date (April 2011) added as reported by ClinicalTrials.gov.
- 28 Sep 2011 Status changed from active, no longer recruiting to completed.